On March 17, 2017, the FOURIER trial lead investigators announced that the PCSK9 inhibitor evolocumab (manufactured by AMGEN) significantly reduced the risk of cardiovascular events by 15%. The detailed results from the FOURIER outcomes trial were presented at the American College of Cardiology's 66th Annual Scientific Session Friday, March 17 in Washington, D.C.

According to the new data, inhibition of PCSK9 with evolocumab on a background of statin therapy lowered LDL cholesterol levels to a median of 30 mg per deciliter (0.78 mmol per liter) and reduced the risk of cardiovascular events. These findings indicate that patients with atherosclerotic cardiovascular disease may have additional benefits from lowering their LDL cholesterol levels below current targets.

The Trial also revealed consistent results in patients across all baseline LDL-C quartiles and no significant adverse effects as compared to placebo, except 2.1% injection-site reactions versus 1.6% on placebo. Soon, another clinical trial by the name "EBBINGHAUS study" will provide data on cognitive safety of the new drug.

The FOURIER results were published on March 17, 2017 in the New England Journal of Medicine